PDCD1 and non-small cell lung carcinoma: Recently, Zhou et al. conducted a phase IB study of autologous CIK cells in combination with Sintilimab (a monoclonal antibody against PD-1) plus chemotherapy in patients with advanced NSCLC [30].The authors clearly demonstrated well-tolerated effects and encouraging efficacy in patients with previously untreated advanced NSCLC.